Clinical trial · Interventional
Study of Home Full Blood Count (FBC) Telemonitoring Device for Chemotherapy Patient
Effectiveness and Feasibility Study of a New Home Full Blood Count Tele-monitoring Device for Cancer Patients Receiving Chemotherapy (ETC1)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Zodiac, a Philips healthcare telemonitoring system has been devised to allow cancer patients receiving chemotherapy to test their blood count at home. It is anticipated that the system will allow patients and clinicians to reduce the toxic effects of chemotherapy by early diagnosis of neutropenia, anaemia and any associated complications of chemotherapy. It is also anticipated that the system will also allow clinicians to better manage the scheduling of chemotherapy regimes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Home Telemonitoring System (The Zodiac, Philips Health care) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Home Monitoring
- description
- All participants will receive a home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home.
- interventionNames
- Device: Home Telemonitoring System (The Zodiac, Philips Health care)
Primary outcomes (1)
- measure
- Capillary Blood Sample
- timeFrame
- 3 times per week for 6 weeks
- description
- To achieve a read out result of a full blood count (haemoglobin, haematocrit, white cell count and neutrophil count) from capillary blood obtained by finger prick and analysed in the Philips Zodiac system that varies by no more than 15% from a sample reported by the standard hospital based laboratory analyser for white cell count, haemoglobin and haematocrit using venous blood.
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female, age \> 18. 2. Able to give informed written consent in the English language. 3. Diagnosis of cancer and receiving chemotherapy or with a planned chemotherapy start date within 2 weeks of enrolment. 4. Patients who are able to perform finger prick test to obtain capillary blood. Exclusion Criteria: 1. Inability to give informed consent due to mental capacity or language problems. 2. Patients at risk of bruising or bleeding as a result of their disease or treatment. 3. Patients at risk of bruising or bleeding due to anticoagulants (heparin or warfarin), aspirin or thrombocytopenia (platelet count \<80). 4. Patients with diabetes mellitus 5. Patients with peripheral neuropathy
References
Publications (0)
Data not yet available